Found: 21
Select item for more details and to access through your institution.
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
- Published in:
- BJU International, 2017, v. 119, n. 1, p. 30, doi. 10.1111/bju.13493
- By:
- Publication type:
- Article
Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren.
- Published in:
- Die Urologie, 2024, v. 63, n. 1, p. 67, doi. 10.1007/s00120-023-02197-z
- By:
- Publication type:
- Article
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266702
- By:
- Publication type:
- Article
Prognostic Performance of RECIP 1.0 Based on [<sup>18</sup>F]PSMA-1007 PET in Prostate Cancer Patients Treated with [<sup>177</sup>Lu]Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 4, p. 560, doi. 10.2967/jnumed.123.266702
- By:
- Publication type:
- Article
Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen--Directed Radioligand Therapy.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1272, doi. 10.2967/jnumed.122.265379
- By:
- Publication type:
- Article
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy.
- Published in:
- Prostate, 2022, v. 82, n. 14, p. 1406, doi. 10.1002/pros.24414
- By:
- Publication type:
- Article
Reliability of continuous vital sign monitoring in post-operative patients employing consumer-grade fitness trackers: A randomised pilot trial.
- Published in:
- Digital Health, 2024, p. 1, doi. 10.1177/20552076241254026
- By:
- Publication type:
- Article
Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach.
- Published in:
- Biology (2079-7737), 2022, v. 11, n. 5, p. 660, doi. 10.3390/biology11050660
- By:
- Publication type:
- Article
SUV<sub>mean</sub> on baseline [<sup>18</sup>F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [<sup>177</sup>Lu]Lu-PSMA I&T.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 11, p. 3465, doi. 10.1007/s00259-023-06281-6
- By:
- Publication type:
- Article
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4727, doi. 10.1007/s00259-022-05910-w
- By:
- Publication type:
- Article
Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA I&T during long-term follow-up.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 12, p. 4262, doi. 10.1007/s00259-022-05853-2
- By:
- Publication type:
- Article
Diverse PSMA expression in primary prostate cancer: reason for negative [<sup>68</sup>Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 11, p. 3938, doi. 10.1007/s00259-022-05831-8
- By:
- Publication type:
- Article
Matched-pair analysis of [<sup>177</sup>Lu]Lu-PSMA I&T and [<sup>177</sup>Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 9, p. 3269, doi. 10.1007/s00259-022-05744-6
- By:
- Publication type:
- Article
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 6, p. 2024, doi. 10.1007/s00259-020-05160-8
- By:
- Publication type:
- Article
False-negative 18F-PSMA-1007 PET/CT in metastatic prostate cancer related to high physiologic liver uptake.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 8, p. 2044, doi. 10.1007/s00259-019-04645-5
- By:
- Publication type:
- Article
<sup>68</sup>Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 1, p. 168, doi. 10.1007/s00259-019-04524-z
- By:
- Publication type:
- Article
Preliminary results on response assessment using <sup>68</sup>Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 4, p. 602, doi. 10.1007/s00259-017-3887-x
- By:
- Publication type:
- Article
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [ 177 Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome.
- Published in:
- Cancers, 2021, v. 13, n. 17, p. 4270, doi. 10.3390/cancers13174270
- By:
- Publication type:
- Article
Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 5, p. 1390, doi. 10.3390/jcm9051390
- By:
- Publication type:
- Article
Detection Rate of 68 Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy.
- Published in:
- Biomedicines, 2020, v. 8, n. 11, p. 511, doi. 10.3390/biomedicines8110511
- By:
- Publication type:
- Article
A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
- Published in:
- Prostate, 2016, v. 76, n. 13, p. 1160, doi. 10.1002/pros.23202
- By:
- Publication type:
- Article